Harbour Investments Inc. Reduces Stock Holdings in Pfizer Inc. (NYSE:PFE)

Harbour Investments Inc. decreased its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 14.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 62,692 shares of the biopharmaceutical company's stock after selling 10,341 shares during the period. Harbour Investments Inc.'s holdings in Pfizer were worth $1,663,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of PFE. Charles Schwab Investment Management Inc. raised its stake in shares of Pfizer by 19.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company's stock valued at $4,124,330,000 after acquiring an additional 25,315,159 shares during the last quarter. Raymond James Financial Inc. bought a new stake in shares of Pfizer during the 4th quarter valued at $274,694,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of Pfizer by 22.4% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 38,068,879 shares of the biopharmaceutical company's stock valued at $1,101,713,000 after acquiring an additional 6,977,587 shares during the last quarter. Fisher Asset Management LLC grew its holdings in Pfizer by 79.5% during the fourth quarter. Fisher Asset Management LLC now owns 11,148,116 shares of the biopharmaceutical company's stock valued at $295,760,000 after purchasing an additional 4,938,209 shares during the period. Finally, Van ECK Associates Corp increased its stake in Pfizer by 28.5% in the fourth quarter. Van ECK Associates Corp now owns 21,286,805 shares of the biopharmaceutical company's stock valued at $564,739,000 after purchasing an additional 4,726,549 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company's stock.

Remove Ads

Pfizer Stock Performance

Shares of Pfizer stock traded down $0.14 during trading hours on Wednesday, reaching $26.17. The company had a trading volume of 24,603,876 shares, compared to its average volume of 35,755,450. The firm has a market cap of $148.34 billion, a PE ratio of 18.57, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61. Pfizer Inc. has a one year low of $24.48 and a one year high of $31.54. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The business has a fifty day simple moving average of $26.21 and a 200 day simple moving average of $27.09.

Pfizer (NYSE:PFE - Get Free Report) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.15. The business had revenue of $17.76 billion for the quarter, compared to analysts' expectations of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business's revenue for the quarter was up 24.7% compared to the same quarter last year. During the same period in the prior year, the company posted $0.10 EPS. On average, analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Analysts Set New Price Targets

PFE has been the subject of a number of recent analyst reports. Guggenheim restated a "buy" rating on shares of Pfizer in a research report on Tuesday. Hsbc Global Res upgraded Pfizer to a "strong-buy" rating in a report on Monday, March 10th. StockNews.com downgraded shares of Pfizer from a "strong-buy" rating to a "buy" rating in a report on Wednesday, November 20th. Truist Financial reduced their price target on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating for the company in a report on Wednesday, December 18th. Finally, Bank of America restated a "neutral" rating and set a $29.00 price objective on shares of Pfizer in a report on Tuesday, December 10th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have issued a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $31.92.

Insiders Place Their Bets

In other Pfizer news, Director Ronald E. Blaylock purchased 19,457 shares of the firm's stock in a transaction that occurred on Thursday, February 13th. The stock was bought at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the purchase, the director now directly owns 27,707 shares in the company, valued at $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.06% of the company's stock.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.